Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Morphosys in Transformative Deal With Celgene, Morphs Into FIBCO

This article was originally published in The Pink Sheet Daily

Executive Summary

Morphosys and Celgene have agreed to jointly develop MOR202 for multiple myeloma, and to co-promote it in Europe. The deal allows Morphosys for the first time to participate in the commercialization of one of its products and decisively validates commercial interest in one of the industry’s hot oncology targets

You may also be interested in...



MorphoSys Nabs GSK As Latest Partner For RA Drug

The British pharma is expanding its portfolio in rheumatoid arthritis through a mid-stage tie-up with German biotech MorphoSys. GSK will take over all development of the antibody and could pay milestones up to €425 million.

Celgene Dips Into The Antibody Well Once More, Partners With Sutro

Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.

MorphoSys Finds Right Time To Focus On Pipeline With AbD Serotec Sale To Bio-Rad Labs

MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS075891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel